Alzamend Neuro, Inc. (NASDAQ:ALZN) Short Interest Up 13.0% in March

Alzamend Neuro, Inc. (NASDAQ:ALZNGet Free Report) was the target of a significant growth in short interest during the month of March. As of March 15th, there was short interest totalling 51,200 shares, a growth of 13.0% from the February 29th total of 45,300 shares. Based on an average daily trading volume, of 56,100 shares, the days-to-cover ratio is currently 0.9 days. Currently, 1.0% of the shares of the company are sold short.

Alzamend Neuro Trading Down 2.0 %

Shares of ALZN stock opened at $1.00 on Monday. Alzamend Neuro has a 1 year low of $0.74 and a 1 year high of $11.91. The firm’s fifty day simple moving average is $0.95 and its 200 day simple moving average is $1.56. The firm has a market capitalization of $6.87 million, a P/E ratio of -1.01 and a beta of -0.03.

Institutional Investors Weigh In On Alzamend Neuro

Institutional investors and hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. increased its stake in shares of Alzamend Neuro by 6,642.3% in the 3rd quarter. Vanguard Group Inc. now owns 4,095,775 shares of the company’s stock valued at $4,874,000 after acquiring an additional 4,035,028 shares during the last quarter. BlackRock Inc. bought a new stake in Alzamend Neuro during the 3rd quarter worth approximately $709,000. Renaissance Technologies LLC bought a new stake in Alzamend Neuro during the 2nd quarter worth approximately $56,000. Virtu Financial LLC bought a new stake in Alzamend Neuro during the 4th quarter worth approximately $35,000. Finally, HRT Financial LP bought a new stake in Alzamend Neuro during the 4th quarter worth approximately $32,000. Institutional investors own 49.61% of the company’s stock.

About Alzamend Neuro

(Get Free Report)

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.

Featured Stories

Receive News & Ratings for Alzamend Neuro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alzamend Neuro and related companies with MarketBeat.com's FREE daily email newsletter.